Trial Profile
A randomised, double-blind, placebo-controlled study of AGI 001 in the treatment of irritable bowel syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Dec 2020
Price :
$35
*
At a glance
- Drugs Espindolol (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors AGI Therapeutics
- 04 Oct 2006 New trial record.